MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
20.61
-0.66
-3.10%
After Hours: 20.52 -0.09 -0.44% 19:44 03/13 EDT
OPEN
21.41
PREV CLOSE
21.27
HIGH
21.57
LOW
20.54
VOLUME
1.55M
TURNOVER
--
52 WEEK HIGH
28.35
52 WEEK LOW
13.40
MARKET CAP
3.51B
P/E (TTM)
8.96
1D
5D
1M
3M
1Y
5Y
1D
Has ACADIA Pharmaceuticals (ACAD) Pullback Opened A New Opportunity For Investors?
Simply Wall St · 1d ago
Acadia Pharmaceuticals to join Stifel Virtual CNS Forum fireside chat
Reuters · 2d ago
Weekly Report: what happened at ACAD last week (0302-0306)?
Weekly Report · 6d ago
ACADIA Pharmaceuticals (ACAD) Valuation After CHMP Setback On Trofinetide For Rett Syndrome
Simply Wall St · 03/07 17:32
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (HIMS) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 03/06 06:10
Why ACADIA Pharmaceuticals (ACAD) Is Down 9.1% After EU Setback on Trofinetide Approval Effort
Simply Wall St · 03/06 02:30
ACADIA Pharmaceuticals appoints Jonathan M. Poole to board and audit committee
Reuters · 03/05 11:04
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)
NASDAQ · 03/05 10:07
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.